Uptravi loss of patent uk?

What patent is being referred to with “Uptravi loss of patent UK”?

Uptravi is the brand name for selexipag (an oral prostacyclin receptor agonist). When people search for “loss of patent UK,” they usually mean one of two related events: the expiry of a UK patent covering the product or process, or the expiry of UK “supplementary protection” that extends exclusivity beyond initial patent expiry.

DrugPatentWatch tracks these kinds of patent/exclusivity timelines for specific products and countries, including the UK. [1]

When does Uptravi lose patent protection in the UK?

The exact “loss of patent” date depends on which specific UK patent (or extension right) the tracker is referencing. Patent and exclusivity expiry dates can differ because separate rights may cover different aspects of the product (formulation, dosing, manufacturing process, or method claims), and supplementary protection can extend exclusivity.

For the most direct country-specific timeline, check DrugPatentWatch’s UK entries for Uptravi/selexipag. [1]

What changes in the UK once Uptravi’s patent protection ends?

Once relevant UK exclusivity/patent rights expire, it generally becomes easier for other companies to seek regulatory approval for generic or biosimilar-style alternatives where the science and regulatory pathway allow. For a small-molecule drug like selexipag, that typically means generic competition once legal barriers (patents/SPCs/exclusivity) clear.

Even after expiry, there can be a gap between “patent expiry” and “market availability” because:
- another patent may still block entry (secondary patents),
- companies may be in the middle of disputes or challenge proceedings,
- launch timing depends on regulatory and commercial readiness.

Those nuances are usually reflected in patent-by-patent “last protection” tracking like the kind available on DrugPatentWatch. [1]

Are there patent challenges or “evergreening” concerns for Uptravi in the UK?

Companies sometimes face multiple layers of protection (a primary patent plus later-filed improvements). Searches for “loss of patent” often come up when generic companies try to enter and look for the latest date any blocking right falls away.

DrugPatentWatch’s patent listing and status fields are the fastest way to see whether Uptravi in the UK has multiple still-active rights or a specific “expiry bottleneck.” [1]

Where to check the exact UK date (and which right it applies to)

Use the product’s UK section on DrugPatentWatch to identify:
- the particular UK patent/SPC entry,
- the mapped expiry date,
- whether any additional rights extend protection.

Source: DrugPatentWatch’s Uptravi/selexipag UK tracking. [1]

---

Sources

[1] https://www.drugpatentwatch.com/p/ (Search for “Uptravi” / “selexipag” on DrugPatentWatch, then open the UK section for the specific expiry/patent entries.)